CVB Shares CurveBeam AI Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Medical-imaging commercialization and exceptional recent momentum offer speculative upside from a small base.
Future value: $0.04 (+100.00%) · 6-12 months
Signal breakdown
- ▸Shares surged 15% on heavy volume following commercial growth commentary.
- ▾Below 50-day MA (-7.41%)
- ▾Near 52-week low (3.5% of range)
- ▸~100% upside to price target
Is CVB a buy right now?
Trend: CVB is trading above the 50-day average (+0.00%), RSI 35 — neutral momentum, with a 3-month return of +11.11%.
Valuation & quality: CurveBeam AI Limited trades on price-to-book 0.34; fundamentals show net margin -217.3%, return on equity -59.9%, revenue growth -48.5% year on year.
Our screen: ACCUMULATE (score 1) — Medical-imaging commercialization and exceptional recent momentum offer speculative upside from a small base.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -28.60% | +20.00% | -16.70% | -40.00% | -33.30% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About CurveBeam AI Limited
CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and internationally.
Sector: Healthcare · Industry: Medical Devices · United States · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.